Morphine Sulfate Extended-Release Tablets Recalled for Failed Impurities Specification
Dr. Reddy's Laboratories is recalling Morphine Sulfate Extended-Release Tablets 30 mg (Lot FG13996) nationwide due to failed impurities and degradation specifications.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for a prescription opioid product with failed quality specifications. No illnesses or injuries have been reported in the source material, but morphine products present inherent risk of harm if efficacy or safety are compromised by degradation.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Morphine Sulfate Extended-Release Tablets 30 mg because the product failed to meet required specifications for impurities and degradation. The recall encompasses 532 bottles (100-count size) distributed nationwide. The affected medication is identified by Lot Number FG13996, which expires 09/30/2025.
Patients currently taking this medication should consult their healthcare provider or pharmacist before making any changes to their medication regimen. Those who may have received the affected product should contact their pharmacy or physician for guidance on replacement or alternative treatment options.
The recalled product
- Product
- Morphine Sulfate Extended-Release Tablets 30 mg, 100-count bottles, Rx Only, Manufactured by Mayne Pharma, Greenville, NC 27834, NDC 51862-186-01.
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug — Prescription Opioid
- Hazard
- impurities
- degradation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# FG13996
- Exp 09/30/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27